IMPEDE-PKD: Implementation of Metformin Therapy to Ease Decline of Kidney Function in PKD (IMPEDE-PKD)- A trial of Metformin to slow down disease progression in people with Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Full title: Implementation of Metformin TheraPy to Ease DEcline of Kidney Function in Polycystic Kidney Disease: A randomised placebo-controlled trial.
This study aims to assess whether a widely available drug, Metformin, can slow down the rate at which kidney disease progresses in people with Autosomal Dominant Polycystic Kidney Disease (ADPKD). ADPKD is the 4th most common reason for starting dialysis in Australia.
Study protocol: pending publication
ANZCTR: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=19791&isClinicalTrial=True
Registration number: NCT04939935
IMPEDE-PKD is coordinated by the Australasian Kidney Trials Network (AKTN).
Key features of the AKTN approach
Used a pragmatic design approach: The study design reduced the number of in-person visits to the Kidney Health Service so that follow up can be done remotely/ via telehealth. This was significant in enabling greater participation in the trial and not requiring any adaptation to the teletrial model, which made the trial more feasible.
Strong engagement of Investigators at the primary site: The Investigators were engaged at both the Townsville Primary site and Mt Isa Satellite site, which was useful in enabling activation. Strong relationships between the primary and satellite sites are essential.
AKTN are aiming to open the following trials as teletrials:
This case is part of ACTA’s teletrials web resource which includes more examples of how Clinical Trial Networks (CTNs) and Coordinating Trial Centres (CTCs) have used the teletrial approach in their trials.
Find out more
Please contact the AKTN team:
Laura Hickey, Clinical Operations Manager
E: aktn@uq.edu.au